Publications by authors named "Daniela C M Silva"
Background: The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear.
Methods: We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2-positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo.
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health
January 2022
Article Synopsis
- Recent research suggests fluvoxamine may help prevent hospitalizations in patients with COVID-19, as studied in the TOGETHER trial involving symptomatic Brazilian adults.
- In this randomized, placebo-controlled trial, participants were assigned to receive either fluvoxamine (100 mg twice daily for 10 days) or a placebo, while treatment allocation was kept blind for all involved.
- Out of 9,803 screened patients, the trial included 741 on fluvoxamine and 756 on placebo, with findings indicating superior outcomes for fluvoxamine in reducing COVID-19 related hospitalizations.
Vaccinia virus is responsible for a zoonosis that usually affects cattle and human beings in Brazil. The initial clinical signs of the infection are focal red skin areas, fever, and general symptoms similar to those of a cold. Then, pustules and ulcerated lesions surrounded by edema and erythema follow, as well as local lymphadenopathy that can last for weeks.
View Article and Find Full Text PDF